

Michael H Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3093823/publications.pdf>

Version: 2024-02-01

84
papers

3,158
citations

279487

23
h-index

155451

55
g-index

85
all docs

85
docs citations

85
times ranked

3127
citing authors

#	ARTICLE	IF	CITATIONS
1	Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 763-771.	0.7	4
2	US Antiarrhythmic Drug Treatment for Patients With Atrial Fibrillation: An Insurance Claims-Based Report. Journal of the American Heart Association, 2021, 10, e016792.	1.6	8
3	Hospitalizations and Costs in Primary Prevention ICD Recipients. JACC: Clinical Electrophysiology, 2018, 4, 254-256.	1.3	0
4	Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation: An Analysis Using Administrative Claims Data. Advances in Therapy, 2018, 35, 2069-2080.	1.3	2
5	Impact of Warfarin on Atrial-Fibrillation Outcomes Related to Economic Consumption Patterns: Hospitalization, Cost, and Mortality may be Predictable and Modifiable at the Population Level. Advances in Therapy, 2016, 33, 1579-1599.	1.3	0
6	Patterns of Dofetilide Use for the Treatment of Atrial Fibrillation. Journal of Innovations in Cardiac Rhythm Management, 2016, 7, 2425-2428.	0.2	1
7	A case series of anomalous high pacing lead impedances in normally functioning leads. HeartRhythm Case Reports, 2015, 1, 449-452.	0.2	7
8	A Call for Appropriate Evidence and Outcomes-Based Use and Measurement of Anticoagulation for Atrial Fibrillation: Moving the Population Towards Improved Health Via Multiple Stakeholders. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 1034-1038.	0.5	2
9	Time course of appropriate implantable cardioverter-defibrillator therapy and implications for guideline-based driving restrictions. Heart Rhythm, 2015, 12, 1728-1736.	0.3	16
10	Health Care Burden of Dyspepsia Among Nonvalvular Atrial Fibrillation Patients. Journal of Managed Care Pharmacy, 2014, 20, 391-399.	2.2	0
11	Shared Risk Factors for Anticoagulation in Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 2148-2150.	1.2	1
12	Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter. Advances in Therapy, 2014, 31, 318-332.	1.3	4
13	The relationship between defibrillation threshold and total mortality. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 203-208.	0.6	5
14	Device advisory letters: Readability and comprehension, patient-centered outcomes not to be misinterpreted. Heart Rhythm, 2013, 10, 508-509.	0.3	0
15	Treatment Targets in Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 461-462.	1.2	0
16	Effectiveness of VF induction with DC fiber versus conventional induction methods in patients on chronic amiodarone therapy. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 137-141.	0.6	2
17	Prospective evaluation of cinefluoroscopy and chest radiography for Riata lead defects: implications for future lead screening. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 131-135.	0.6	4
18	Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation. Expert Review of Clinical Pharmacology, 2012, 5, 163-171.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Long-Term Insertable Loop Monitors: How Much Should We Watch to Get an Answer (Diagnosis)?. Journal of Cardiovascular Electrophysiology, 2012, 23, 72-73.	0.8	0
20	Catheter Ablation of Atrial Fibrillation in Octogenarians: The Right "Medicine". Journal of Cardiovascular Electrophysiology, 2012, 23, 694-696.	0.8	0
21	Prevalence and Predictors of Cable Extrusion and Loss of Electrical Integrity with the Riata Defibrillator Lead. Journal of Cardiovascular Electrophysiology, 2012, 23, 1207-1212.	0.8	36
22	A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm, 2011, 8, 685-691.	0.3	19
23	One-Year Treatment Persistence and Potential Adverse Events Among Patients With Atrial Fibrillation Treated With Amiodarone or Sotalol: A Retrospective Claims Database Analysis. Clinical Therapeutics, 2011, 33, 1668-1681.e1.	1.1	15
24	Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 313-320.	0.9	652
25	Total costs and atrial fibrillation ablation success or failure in medicare-aged patients in the United States. Advances in Therapy, 2010, 27, 600-612.	1.3	16
26	The impact of stored atrial rhythm diagnostics in permanent pacemakers and the management of atrial fibrillation: the Vitatron Selection AFm Registry study. Journal of Interventional Cardiac Electrophysiology, 2010, 28, 227-234.	0.6	3
27	Predictors of Early Mortality in Patients Age 80 and Older Receiving Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 981-7.	0.5	20
28	Predicting the Risk of Heart Failure Events and Subsequent Mortality: What Doth the Seer Know?. Journal of Cardiovascular Electrophysiology, 2010, 21, 1224-1225.	0.8	0
29	Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation. Annals of Pharmacotherapy, 2009, 43, 840-848.	0.9	29
30	Influence of structural heart disease on characteristics of atrial fibrillation recurrence in patients with dual-chamber pacemakers. Journal of Electrocardiology, 2009, 42, 128-135.	0.4	3
31	Patterns and Predictors of Discontinuation of Rhythm-Control Drug Therapy in Patients with Newly Diagnosed Atrial Fibrillation. Pharmacotherapy, 2009, 29, 1417-1426.	1.2	17
32	National assessment of medicare prescription plan coverage gaps among patients with atrial fibrillation in the US. Advances in Therapy, 2009, 26, 784-794.	1.3	3
33	Cost of atrial fibrillation in United States managed care organizations. Advances in Therapy, 2009, 26, 847-857.	1.3	81
34	A Novel Method for Sinus Node Modification and Phrenic Nerve Protection in Resistant Cases. Journal of Cardiovascular Electrophysiology, 2009, 20, 689-691.	0.8	18
35	Acute Hemodynamic Effects of Atrial Pacing with Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2009, 20, 894-900.	0.8	24
36	Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Current Medical Research and Opinion, 2009, 25, 3037-3047.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2009, 25, 1215-1220.	0.9	25
38	To the Editorâ€™Response. <i>Heart Rhythm</i> , 2008, 5, 169-170.	0.3	1
39	A Written Policy Increases Compliance With Guidelines for Therapeutic Anticoagulation Prior to Elective Direct Current Cardioversion of Atrial Fibrillation. <i>Journal of Cardiovascular Nursing</i> , 2007, 22, 417-421.	0.6	1
40	Value of Pacemaker Atrial Diagnostic Data in Patients with Paroxysmal Atrial Fibrillation: An Opportunity to Improve Rates of Warfarin Utilization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 580-583.	0.5	7
41	A Prospective Comparison of AV Delay Programming Methods for Hemodynamic Optimization during Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 490-496.	0.8	99
42	Left bundle branch block during orthodromic reciprocating tachycardia: Where is the accessory pathway?. <i>Heart Rhythm</i> , 2006, 3, 610-611.	0.3	6
43	Effect of Short Pulse Width Programming in AutoCapture Devices. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, S70-S72.	0.5	0
44	Polymorphic Ventricular Tachycardia with a Normal QT Interval Following Azithromycin. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, 1221-1222.	0.5	53
45	Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study. <i>Archives of Internal Medicine</i> , 2005, 165, 1185.	4.3	207
46	A new automated algorithm for optimizing AV delay to improve global LV contractile function with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2005, 2, S287.	0.3	7
47	Cardiac Resynchronization Therapy: A Potential Option for Congenitally Corrected Transposition of the Great Vessels. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2293-2296.	0.3	12
48	Amiodarone Prophylaxis Reduces Major Cardiovascular Morbidity and Length of Stay after Cardiac Surgery: A Meta-Analysis. <i>Annals of Internal Medicine</i> , 2005, 143, 327.	2.0	105
49	Cardiac pacing: the state of the art. <i>Lancet, The</i> , 2004, 364, 1701-1719.	6.3	113
50	Diagnostic value of single versus dual chamber electrograms recorded from an implantable defibrillator. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 9, 49-53.	0.6	11
51	Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 397-400.	0.9	5
52	Maintenance of sinus rhythm in patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2003, 42, 20-29.	1.2	276
53	Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. <i>American Heart Journal</i> , 2003, 145, 665-669.	1.2	11
54	Atrial fibrillation after coronary surgery: comparison between different health care systems. <i>International Journal of Cardiology</i> , 2002, 82, 209-218.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Effect of amiodarone ± diltiazem ± beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting. American Journal of Cardiology, 2002, 89, 1126-1128.	0.7	10
56	Kearns-Sayre Syndrome: Association with Long QT Syndrome?. Journal of Cardiovascular Electrophysiology, 2002, 13, 184-185.	0.8	24
57	The Immediate Reproducibility of T Wave Alternans During Bicycle Exercise. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1185-1191.	0.5	23
58	A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin. Annals of Emergency Medicine, 2002, 40, 187-192.	0.3	33
59	Prevalence of central venous occlusion in patients with chronic defibrillator leads. American Heart Journal, 2001, 141, 813-816.	1.2	101
60	Postoperative atrial fibrillation after heart surgery: What are the goals of prevention?. American Heart Journal, 2001, 141, 691-693.	1.2	4
61	Cardiac Risk Assessment in Noncardiac Thoracic Surgery. Seminars in Thoracic and Cardiovascular Surgery, 2001, 13, 137-146.	0.4	6
62	Electrogram Polarity and Cavotricuspid Isthmus Block During Ablation of Typical Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2001, 12, 393-399.	0.8	56
63	Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. American Journal of Cardiology, 2001, 87, 649-651.	0.7	93
64	Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (the postoperative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	68
65	Clinical outcomes and costs associated with a first episode of uncomplicated atrial fibrillation presenting to the emergency room. American Journal of Cardiology, 2001, 88, 74-76.	0.7	14
66	Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter. American Journal of Cardiology, 2001, 88, 1428-1431.	0.7	14
67	Diastolic Dysfunction in the Presence of Left Ventricular Systolic Dysfunction: Implications of Å-Adrenergic Blocking Therapy. Congestive Heart Failure, 2001, 7, 71-76.	2.0	1
68	Prevalence and significance of Exit Block During Arrhythmias Arising in Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2000, 11, 379-386.	0.8	15
69	Effect of Chronic Amiodarone Therapy on Defibrillation Energy Requirements in Humans. Journal of Cardiovascular Electrophysiology, 2000, 11, 736-740.	0.8	52
70	Comparison of Endocardial Activation Times at Effective and Ineffective Ablation Sites Within the Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2000, 11, 155-159.	0.8	16
71	Outcome of men with ischemic cardiomyopathy, asymptomatic nonsustained ventricular tachycardia, and negative electrophysiologic studies. American Journal of Cardiology, 2000, 85, 119-121.	0.7	8
72	Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment. Journal of Cardiovascular Pharmacology and Therapeutics, 2000, 5, 259-266.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Effects of Digoxin on Acute, Atrial Fibrillation—Induced Changes in Atrial Refractoriness. <i>Circulation</i> , 2000, 102, 2503-2508.	1.6	61
74	Diagnostic value of tachycardia features and pacing maneuvers during paroxysmal supraventricular tachycardia. <i>Journal of the American College of Cardiology</i> , 2000, 36, 574-582.	1.2	327
75	Bayesian Persuasion. <i>Circulation</i> , 1999, 100, e68-72.	1.6	4
76	Effects of β^2 -Adrenergic Blocking Therapy on Left Ventricular Diastolic Relaxation Properties in Patients With Dilated Cardiomyopathy. <i>Circulation</i> , 1999, 100, 729-735.	1.6	40
77	Target Temperatures of 48°C versus 60°C During Slow Pathway Ablation:. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 799-803.	0.8	5
78	Effect of electrode polarity on the energy required for transthoracic atrial defibrillation. <i>American Journal of Cardiology</i> , 1999, 84, 228-230.	0.7	12
79	Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract. <i>American Journal of Cardiology</i> , 1999, 84, 1266-1268.	0.7	32
80	Sudden Death in a 55-Year-Old Woman With Systemic Lupus Erythematosus. <i>Circulation</i> , 1998, 98, 271-275.	1.6	6
81	Silent ischemic cardiomyopathy and left coronary ostial stenosis secondary to radiation therapy. <i>Clinical Cardiology</i> , 1996, 19, 260-262.	0.7	5
82	Waldenstrom's macroglobulinemia transformed into immunoblastic lymphoma presenting with malignant ascites. , 1996, 51, 249-250.		11
83	The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine to monkeys. <i>Annals of Neurology</i> , 1991, 29, 677-679.	2.8	51
84	Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism. <i>Movement Disorders</i> , 1991, 6, 111-118.	2.2	107